Melanoma and Skin Cancer Data You May Have Missed at ESMO 2026

The 2026 European Society for Medical Oncology (ESMO) Congress, featured several updates across melanoma and cutaneous oncology that may shape how clinicians time immunotherapy around surgery and approach uveal melanoma, a disease that has historically had limited treatment options. Three-year data from the phase 3 NADINA trial (NCT04949113) reinforced the role of neoadjuvant immunotherapy in resectable stage III melanoma, while 2 phase 2 studies evaluated the protein kinase C (PKC) inhibitor darovasertib in both the metastatic and neoadjuvant uveal melanoma settings. In cutaneous squamous cell carcinoma (cSCC), long-term results from the phase 3 C-POST (NCT03969004) and KEYNOTE-630 (NCT03833167) trials offered contrasting pictures of adjuvant PD-1 inhibition following surgery and radiotherapy. Here are 5 readouts from the meeting that you may have missed.^1-5